Novation Releases Its Latest Transcatheter Cardiovascular Therapeutics Report to Help Members Understand and Prepare for New Technologies
IRVING, Texas, March 20, 2012 /PRNewswire/ -- Novation, the leading health care supply contracting company, announces the release of its most recent Transcatheter Cardiovascular Therapeutics Report. This report is produced by Novation's cardiology staff and is intended to help VHA, UHC and Provista members understand and prepare for new cardiology technologies.
The Novation cardiology team compiled this report following their attendance late last year at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting. The TCT is the world's largest educational meeting specializing in interventional cardiovascular medicine and the latest advances in current therapies and clinical research. The conference also showcases technologies and devices not yet available in the United States.
By attending the TCT meeting and learning about new trends and devices, the Novation cardiovascular team can advise members about the impact of upcoming technologies before they are approved by the U.S. Food and Drug Administration.
Novation's report focuses on several emerging technologies and trends. Areas of focus in this report include transcatheter aortic valve replacement, high blood pressure therapy, drug-eluting balloons, and bioabsorbable coronary stents, as well as coronary, peripheral vascular, structural heart, and heart rhythm products and technology trends.
Some of the devices, such as the percutaneous heart valves, have recently been approved. Other products, such as the drug-eluting balloon, bioabsorbable coronary stent and renal denervation, are in clinical trials and device development, but demonstrate promising early results. This report highlights these and other new cardiovascular devices in a condensed format.
"The intent of our report is to provide clinical and economic highlights of these new technologies that have a high probability of impacting the member hospitals we serve," said Michael Vintges, vice president, physician preference, contract and program services, Novation. "Novation is committed to helping the hospitals we serve continue to provide the highest quality care, while simultaneously driving supply costs down."
To view the entire report, please visit https://www.novationco.com/pressroom/industry_info.
About Novation, Winner of the Ethics Inside® Certification
Founded in 1998, Novation is the leading health care supply contracting company for the more than 65,000 members of VHA Inc. and UHC, two national health care alliances, and Provista, LLC. Novation provides alliance members with sourcing services, as well as information and data services. Based in Irving, Tex, Novation develops and manages competitive contracts with more than 600 suppliers. VHA, UHC, and Provista members used Novation contracts to purchase more than $40 billion in products and services in 2011. Novation recently earned the coveted Ethics Inside® Certification from Ethisphere Institute, a leading international think tank dedicated to the research and promotion of best practices in corporate ethics and compliance, and is the only health care group purchasing organization to earn this distinction.